Last reviewed · How we verify
LY03010; paliperidone palmitate
LY03010; paliperidone palmitate is a Small molecule drug developed by Luye Pharma Group Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | LY03010; paliperidone palmitate |
|---|---|
| Sponsor | Luye Pharma Group Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder (PHASE1)
- Relative Bioavailability of LY03010 Compared to Listed Drug (PHASE1)
- Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia Patients (PHASE1)
- A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY03010; paliperidone palmitate CI brief — competitive landscape report
- LY03010; paliperidone palmitate updates RSS · CI watch RSS
- Luye Pharma Group Ltd. portfolio CI
Frequently asked questions about LY03010; paliperidone palmitate
What is LY03010; paliperidone palmitate?
LY03010; paliperidone palmitate is a Small molecule drug developed by Luye Pharma Group Ltd..
Who makes LY03010; paliperidone palmitate?
LY03010; paliperidone palmitate is developed by Luye Pharma Group Ltd. (see full Luye Pharma Group Ltd. pipeline at /company/luye-pharma-group-ltd).
What development phase is LY03010; paliperidone palmitate in?
LY03010; paliperidone palmitate is in Phase 1.
Related
- Manufacturer: Luye Pharma Group Ltd. — full pipeline